Consistently, SGSM2 exhibited significantly lower expression levels in BC patients with TP53, BRCA2, or PIK3R1 (PIK3CA suppressed domain) mutation (Figure S10(a), ***P < 0.001; B, ***P < 0.001 and C, *P = 0.037), and higher levels of SGSM2 in BC patients were significantly associated with a low risk of recurrence (Figure S11(a), **P = 0.002, CI = 59.92, risk groups hazard ratio = 1.82). This evidence concerns the gene TP53 and breast cancer.